Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aroa Biosurgery Ltd ( (AU:ARX) ) has issued an announcement.
Aroa Biosurgery has notified the market of the cessation of several classes of equity-based incentives, including restricted stock units, options and performance rights. The instruments, covering a combined 336,541 potential securities, lapsed or expired between February and March 2026 after conditions were not met or options were not exercised, resulting in a reduction of potential future dilution for existing shareholders and a modest simplification of the company’s capital structure.
The most recent analyst rating on (AU:ARX) stock is a Hold with a A$0.60 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
More about Aroa Biosurgery Ltd
Aroa Biosurgery Ltd is a medical technology company listed on the ASX under the code ARX. It operates in the biosurgery and wound care sector, developing and commercialising biologically derived surgical and soft-tissue repair products for healthcare markets.
Average Trading Volume: 125,025
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$190M
For detailed information about ARX stock, go to TipRanks’ Stock Analysis page.